Amendment to Executive Employment by and between the Company and Catherine Madigan, M.D., dated as of February 26, 2024
Exhibit 10.25
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT
This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of the 26th day of February, 2024 (the “Execution Date”), between CATHERINE MADIGAN, M.D. (“Executive”) and Syndax Pharmaceuticals, Inc. (the “Company”) and supplements the terms of that certain executive employment agreement by and between the Parties, dated as of March 1, 2022 (the “Agreement”). Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.
RECITALS
AGREEMENT
NOW, THEREFORE, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:
* * * * *
IN WITNESS WHEREOF, the parties have executed this Amendment on the Execution Date written above.
|
|
|
|
|
|
|
|
| ||||||
Syndax Pharmaceuticals, Inc. |
|
| EXECUTIVE | |||||||||||
|
|
|
|
| ||||||||||
By: |
/s/ Luke J. Albrecht |
| By: |
/s/ Catherine Madigan, M.D. | ||||||||||
|
|
|
|
|
|
|
| |||||||
Name: | Luke J. Albrecht |
|
| Name: | Catherine Madigan, M.D. | |||||||||
Title: |
| General Counsel |
|
|
|
|
|
|
1.